• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patheon to acquire Banner Pharmacaps

Patheon to acquire Banner Pharmacaps

October 30, 2012
CenterWatch Staff

Patheon, a Durham, N.C.-based provider of contract development and manufacturing services, has signed a definitive agreement with Vion, a global manufacturer of foodstuffs and ingredients based in the Netherlands, to acquire Banner Pharmacaps, a High Point, N.C.-based specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

The acquisition will be structured as a purchase of all of the shares of the entities through which Banner conducts its operations, for a purchase price of $255 million, subject to working capital and other adjustments. The acquisition is subject to applicable regulatory approvals and other customary terms and conditions, and is expected to close by the end of calendar 2012.

Through the acquisition, Patheon will gain Banner’s High Point location, as well as research labs and manufacturing facilities in The Netherlands, Canada and Mexico.

"The acquisition of Banner advances our strategic plan put in place in 2011, fully aligning with Patheon's intent to be the leader in oral dosage development and manufacturing services,” said James C. Mullen, CEO of Patheon. “The transaction provides us with a well-balanced portfolio of proprietary products, state-of-the-art facilities with enhanced capabilities, as well as an expanded geographical presence. We believe our visibility within the industry will be further strengthened as we pass the $1 billion-revenue mark."

Peter Beckers, chairman of Banner Pharmacaps and executive board member of Vion, said, "Patheon shares many interfaces with Banner's field of activities and offers opportunities for further growth over the coming years. The sale of Banner is a strategic transaction for both organizations. It allows Vion to focus on its core business of food and ingredients, while aligning Banner with a global company that is known for its focus on quality and customer service in the pharmaceutical industry. We are convinced that this transaction represents the best outcome for Banner's customers, partners and for our people, who will benefit from the scale opportunities of being a part of an organization such as Patheon."

In support of the transaction, Patheon has received commitments for financing that will be applied to fund the acquisition and associated expenses, retire existing debt and used for general corporate purposes. Such commitments are subject to customary terms and conditions.

UBS Securities is acting as exclusive M&A advisor, and Reed Smith and Skadden, Arps, Slate, Meagher & Flom are acting as legal advisors to Patheon. Rabobank International and Rothschild are acting as exclusive financial advisors, and Becker, Glynn, Muffly, Chassin & Hosinski is acting as legal advisor to Vion. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing